# Chemotherapy and Bevacizumab With or Without Radiofrequency Ablation in Treating Unresectable Liver Metastases in Patients With Colorectal Cancer

> **NCT00043004** · PHASE2 · TERMINATED · sponsor: **European Organisation for Research and Treatment of Cancer - EORTC** · enrollment: 119 (actual)

## Conditions studied

- Colorectal Cancer
- Metastatic Cancer

## Interventions

- **BIOLOGICAL:** bevacizumab
- **DRUG:** FOLFOX regimen
- **DRUG:** fluorouracil
- **DRUG:** leucovorin calcium
- **DRUG:** oxaliplatin
- **PROCEDURE:** conventional surgery
- **PROCEDURE:** radiofrequency ablation

## Key facts

- **NCT ID:** NCT00043004
- **Lead sponsor:** European Organisation for Research and Treatment of Cancer - EORTC
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2002-05
- **Primary completion:** 2007-06
- **Final completion:** —
- **Target enrollment:** 119 (ACTUAL)
- **Why stopped:** low accrual
- **Last updated:** 2012-09-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00043004

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00043004, "Chemotherapy and Bevacizumab With or Without Radiofrequency Ablation in Treating Unresectable Liver Metastases in Patients With Colorectal Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00043004. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*